Strain identifier

BacDive ID: 138348

Type strain: No

Species: Staphylococcus aureus

Strain history: CIP <- 2000, P. Courvalin, Inst. Pasteur, Paris, France <- K. Hiramatsu, Tokyo, Japan: strain Mu3

NCBI tax ID(s): 1280 (species)

For citation purpose refer to the digital object identifier (doi) of the current version.
Archive
version 8.1 (current version):
version 8:
version 7.1:
version 7:
version 6:
version 5:
version 4.1:
version 4:
version 3:
version 2.1:
version 8.1 (current version)

General

@ref: 39515

BacDive-ID: 138348

keywords: genome sequence, Bacteria, aerobe, mesophilic, Gram-positive

description: Staphylococcus aureus CIP 106415 is an aerobe, mesophilic, Gram-positive bacterium of the family Staphylococcaceae.

NCBI tax id

  • NCBI tax id: 1280
  • Matching level: species

strain history

  • @ref: 39515
  • history: CIP <- 2000, P. Courvalin, Inst. Pasteur, Paris, France <- K. Hiramatsu, Tokyo, Japan: strain Mu3

doi: 10.13145/bacdive138348.20230509.8.1

Name and taxonomic classification

LPSN

  • @ref: 20215
  • description: domain/bacteria
  • keyword: phylum/bacillota
  • domain: Bacteria
  • phylum: Bacillota
  • class: Bacilli
  • order: Caryophanales
  • family: Staphylococcaceae
  • genus: Staphylococcus
  • species: Staphylococcus aureus
  • full scientific name: Staphylococcus aureus Rosenbach 1884 (Approved Lists 1980)
  • synonyms

    • @ref: 20215
    • synonym: Staphylococcus aureus subsp. anaerobius

@ref: 39515

domain: Bacteria

phylum: Firmicutes

class: Bacilli

order: Caryophanales

family: Staphylococcaceae

genus: Staphylococcus

species: Staphylococcus aureus

type strain: no

Morphology

cell morphology

@refgram stainconfidencecell shapemotility
69480positive100
39515positivecoccus-shapedno

colony morphology

  • @ref: 39515

Culture and growth conditions

culture medium

@refnamegrowthcompositionlink
39515MEDIUM 72- for trypto casein soja agaryesDistilled water make up to (1000.000 ml);Trypto casein soy agar (40.000 g)
39515CIP Medium 72yeshttps://catalogue-crbip.pasteur.fr/fiche_milieu.xhtml?crbip=72

culture temp

@refgrowthtypetemperaturerange
39515positivegrowth37mesophilic
56732positivegrowth37mesophilic
39515positivegrowth22-45
39515nogrowth10psychrophilic

Physiology and metabolism

oxygen tolerance

@refoxygen tolerance
56732aerobe
39515facultative anaerobe

spore formation

  • @ref: 69480
  • spore formation: no
  • confidence: 99.68

metabolite utilization

@refChebi-IDmetaboliteutilization activitykind of utilization tested
39515606565hippurate+hydrolysis
3951517632nitrate+reduction
3951516301nitrite-reduction
6837516199urea-hydrolysis
6837529016arginine+hydrolysis
6837518257ornithine-degradation
683754853esculin-hydrolysis
6837517634D-glucose+fermentation
6837515824D-fructose+fermentation
6837516024D-mannose+fermentation
6837517306maltose+fermentation
6837517716lactose+fermentation
6837527082trehalose+fermentation
6837516899D-mannitol+fermentation
6837516634raffinose-fermentation
6837516988D-ribose-fermentation
6837517057cellobiose-fermentation
6837517632nitrate+reduction
6837517992sucrose+fermentation
6837559640N-acetylglucosamine+fermentation
6837532528turanose+fermentation
6837522599arabinose-fermentation

antibiotic resistance

  • @ref: 68375
  • ChEBI: 28368
  • metabolite: novobiocin
  • is antibiotic: yes
  • is sensitive: yes
  • sensitivity conc.: 1.8 µg

metabolite production

@refChebi-IDmetaboliteproduction
6837515688acetoinno
3951535581indoleno

metabolite tests

@refChebi-IDmetabolitevoges-proskauer-test
6837515688acetoin-
3951515688acetoin+

enzymes

@refvalueactivityec
68375beta-glucuronidase-3.2.1.31
68375pyrrolidonyl arylamidase+3.4.19.3
68375alkaline phosphatase+3.1.3.1
68375L-arginine arylamidase-
68375beta-galactosidase-3.2.1.23
68375beta-glucosidase-3.2.1.21
68375ornithine decarboxylase-4.1.1.17
68375arginine dihydrolase+3.5.3.6
68375urease-3.5.1.5
39515oxidase-
39515beta-galactosidase+3.2.1.23
39515alcohol dehydrogenase-1.1.1.1
39515gelatinase-
39515amylase-
39515DNase+
39515caseinase+3.4.21.50
39515catalase+1.11.1.6
39515coagulase+
39515tween esterase+
39515gamma-glutamyltransferase-2.3.2.2
39515lecithinase-
39515lipase+
39515lysine decarboxylase-4.1.1.18
39515ornithine decarboxylase-4.1.1.17
39515phenylalanine ammonia-lyase-4.3.1.24
39515protease+
39515urease-3.5.1.5
68382alkaline phosphatase+3.1.3.1
68382esterase (C 4)+
68382esterase lipase (C 8)+
68382lipase (C 14)-
68382leucine arylamidase+3.4.11.1
68382valine arylamidase-
68382cystine arylamidase-3.4.11.3
68382trypsin-3.4.21.4
68382alpha-chymotrypsin-3.4.21.1
68382acid phosphatase+3.1.3.2
68382naphthol-AS-BI-phosphohydrolase+
68382alpha-galactosidase-3.2.1.22
68382beta-galactosidase-3.2.1.23
68382beta-glucuronidase-3.2.1.31
68382alpha-glucosidase+3.2.1.20
68382beta-glucosidase-3.2.1.21
68382N-acetyl-beta-glucosaminidase-3.2.1.52
68382alpha-mannosidase-3.2.1.24
68382alpha-fucosidase-3.2.1.51

API zym

@refControlAlkaline phosphataseEsteraseEsterase LipaseLipaseLeucine arylamidaseValine arylamidaseCystine arylamidaseTrypsinalpha- ChymotrypsinAcid phosphataseNaphthol-AS-BI-phosphohydrolasealpha- Galactosidasebeta- Galactosidasebeta- Glucuronidasealpha- Glucosidasebeta- GlucosidaseN-acetyl-beta- glucosaminidasealpha- Mannosidasealpha- Fucosidase
39515-+++-+----++---+----

API ID32STA

@refUREADH ArgODCESCGLUFRUMNEMALLACTREMANRAFRIBCELNITVPbeta GALArgAPALPyrANOVOSACNAGTURARAbeta GUR
56732-+--+++++++---+---++-+++--

API biotype100

@refGLUFRUGALTREMNESBEMELSACRAFMTEMALLACLTEMbGaMaGaCELGENMbGuESCRIBARAXYLPLERHAFUCMLZDARLLARLXLTDULTAGGLYINOMANMTLTURSORADOHBGLYXERYMDG3MDGSATMUCLTATDTATMTATDMLTLMLTCATETATETTECITGRTGAT2KG5KGTRYNAGGNTPACPATpOBEQATGTEmOBEBATPPATCMTTGEBETPCEABTHINLATCAPCYTHISSUCFUMGREGYTAVTETNTTNGLNITA3OBUAPTGTTPRODALALALASERMNTPROPTYR2KT
39515+++++--+-++++----+-+------+----+-+-+-------------+------++-++--------------+---++-----+--+++--+---+

Isolation, sampling and environmental information

isolation

@refcountryorigin.countrycontinentsample type
39515JapanJPNAsia
56732JapanJPNAsiaHuman lung
39515JapanJPNAsiaHuman, Lung

isolation source categories

Cat1Cat2Cat3
#Host#Human
#Host Body-Site#Oral cavity and airways#Lung

Safety information

risk assessment

  • @ref: 39515
  • biosafety level: 2
  • biosafety level comment: Risk group (French classification)

Sequence information

Genome sequences

  • @ref: 66792
  • description: Staphylococcus aureus strain NRS2
  • accession: 1280.4823
  • assembly level: wgs
  • database: patric
  • NCBI tax ID: 1280

Genome-based predictions

predictions

traitpredictionconfidencetraining_data
spore-formingno83no
motileno89.009no
gram-positiveyes89.308no
anaerobicno99.469yes
aerobicyes89.852yes
halophileyes93.135no
spore-formingno92.562no
glucose-utilyes89.161no
flagellatedno91.392no
thermophileno99.763yes
glucose-fermentyes86.147yes

External links

@ref: 39515

culture collection no.: CIP 106415, ATCC 700698, CCUG 45316, Mu 3

literature

topicPubmed-IDtitleauthorsjournalDOIyearmeshtopic2
Pathogenicity9684652The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan.Hiramatsu KAm J Med10.1016/s0002-9343(98)00149-11998Anti-Bacterial Agents/*pharmacology, Drug Resistance, Microbial, *Drug Resistance, Multiple, Humans, Japan, *Methicillin Resistance, Microbial Sensitivity Tests, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology
Metabolism9738837Activated cell-wall synthesis is associated with vancomycin resistance in methicillin-resistant Staphylococcus aureus clinical strains Mu3 and Mu50.Hanaki H, Kuwahara-Arai K, Boyle-Vavra S, Daum RS, Labischinski H, Hiramatsu KJ Antimicrob Chemother10.1093/jac/42.2.1991998Acetylglucosamine/metabolism, Anti-Bacterial Agents/*pharmacology, Autolysis, *Bacterial Proteins, Carrier Proteins/biosynthesis/genetics, Cell Wall/metabolism, Culture Media, Drug Resistance, Microbial, Drug Resistance, Multiple, *Hexosyltransferases, Humans, Methicillin Resistance/*physiology, Muramoylpentapeptide Carboxypeptidase/biosynthesis/genetics, N-Acetylmuramoyl-L-alanine Amidase/biosynthesis, Penicillin-Binding Proteins, Peptidoglycan/metabolism, *Peptidyl Transferases, Staphylococcus aureus/drug effects/*metabolism/ultrastructure, Vancomycin/*pharmacologyPathogenicity
Metabolism9786471Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu KJ Antimicrob Chemother10.1093/jac/42.3.3151998Amino Acids/analysis, Drug Resistance, Microbial, Glutamine/chemistry/metabolism, Microbial Sensitivity Tests, Peptides/chemistry/isolation & purification/*metabolism, Peptidoglycan/chemistry/*metabolism, Phenotype, Protein Conformation, Staphylococcus aureus/classification/drug effects/*metabolism, Vancomycin/antagonists & inhibitors/*metabolism/pharmacologyPhylogeny
Cultivation9836124[A novel method of detecting Staphylococcus aureus heterogeneously resistant to vancomycin (hetero-VRSA)].Hanaki H, Inaba Y, Sasaki K, Hiramatsu KJpn J Antibiot1998Anti-Bacterial Agents/*pharmacology, Bacteriological Techniques, Culture Media, Drug Antagonism, Drug Resistance, Microbial, Lactams, Methicillin Resistance, Staphylococcus aureus/*drug effects/*isolation & purification, Vancomycin/*pharmacologyEnzymology
Phylogeny10708580Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method.Kuroda M, Kuwahara-Arai K, Hiramatsu KBiochem Biophys Res Commun10.1006/bbrc.2000.22772000Anti-Bacterial Agents/*pharmacology, Base Sequence, DNA Primers, DNA, Complementary, *Down-Regulation, Drug Resistance, Microbial/genetics, Genes, Bacterial, Nucleic Acid Hybridization, Staphylococcus aureus/drug effects/*genetics, *Up-Regulation, Vancomycin/*pharmacologyPathogenicity
Metabolism11120978A spectrum of changes occurs in peptidoglycan composition of glycopeptide-intermediate clinical Staphylococcus aureus isolates.Boyle-Vavra S, Labischinski H, Ebert CC, Ehlert K, Daum RSAntimicrob Agents Chemother10.1128/AAC.45.1.280-287.20012001Anti-Bacterial Agents/*metabolism/*pharmacology, Chromatography, High Pressure Liquid, Drug Resistance, Microbial, Microbial Sensitivity Tests, Peptidoglycan/chemistry/*metabolism, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/*metabolism, Teicoplanin/metabolism/pharmacology, Vancomycin/metabolism/pharmacology, Vancomycin ResistancePathogenicity
Pathogenicity11257050Combination effect of vancomycin and beta-lactams against a Staphylococcus aureus strain, Mu3, with heterogeneous resistance to vancomycin.Aritaka N, Hanaki H, Cui L, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.45.4.1292-1294.20012001Anti-Bacterial Agents/*pharmacology, Dose-Response Relationship, Drug, Drug Antagonism, Drug Interactions, Drug Therapy, Combination/*pharmacology, Microbial Sensitivity Tests, Peptidoglycan/biosynthesis, Staphylococcus aureus/*drug effects/metabolism, Vancomycin/*pharmacology, *Vancomycin Resistance, beta-Lactams/*pharmacologyMetabolism
Pathogenicity11266410A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital.Wootton M, Howe RA, Hillman R, Walsh TR, Bennett PM, MacGowan APJ Antimicrob Chemother10.1093/jac/47.4.3992001*Hospitals, Humans, Methicillin Resistance, Microbial Sensitivity Tests/*methods, Phenotype, Reproducibility of Results, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/physiology, United Kingdom, Vancomycin/*pharmacology, *Vancomycin ResistancePhenotype
Pathogenicity11304997[Clinical relevance of hetero-VRSA in surgical infections].Okii K, Takesue Y, Yokoyama TNihon Rinsho2001Humans, Methicillin Resistance, Staphylococcal Infections/drug therapy, Staphylococcus aureus/*drug effects, *Vancomycin Resistance
Pathogenicity11427551Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.Walsh TR, Bolmstrom A, Qwarnstrom A, Ho P, Wootton M, Howe RA, MacGowan AP, Diekema DJ Clin Microbiol10.1128/JCM.39.7.2439-2444.20012001Anti-Bacterial Agents/*pharmacology, Double-Blind Method, Humans, Methicillin Resistance, Microbial Sensitivity Tests/*methods/standards, Sensitivity and Specificity, Staphylococcus/*drug effects/isolation & purification, Staphylococcus aureus/drug effects, Vancomycin/*pharmacology, Vancomycin ResistanceEnzymology
Pathogenicity11494564[Investigation of infective endocarditis clinical isolates of methicillin resistant Staphylococcus aureus non-responsive to vancomycin].Takayama Y, Yoshida K, Yamaguchi Y, Nonoyama M, Endo T, Sunakawa KKansenshogaku Zasshi10.11150/kansenshogakuzasshi1970.75.4732001Endocarditis, Bacterial/drug therapy/*microbiology, Humans, Male, *Methicillin Resistance, Middle Aged, Staphylococcal Infections/drug therapy/*microbiology, Staphylococcus aureus/drug effects/*isolation & purification, Vancomycin/*therapeutic useEnzymology
Pathogenicity11724859Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.Ike Y, Arakawa Y, Ma X, Tatewaki K, Nagasawa M, Tomita H, Tanimoto K, Fujimoto SJ Clin Microbiol10.1128/JCM.39.12.4445-4451.20012001Anti-Bacterial Agents/pharmacology, DNA, Bacterial/analysis, Electrophoresis, Gel, Pulsed-Field, *Hospitals, Humans, Japan/epidemiology, *Methicillin Resistance, Microbial Sensitivity Tests, *Population Surveillance, Staphylococcal Infections/epidemiology/microbiology/*transmission, Staphylococcus aureus/*drug effects, Vancomycin/pharmacology, *Vancomycin ResistanceEnzymology
Pathogenicity12718825Emergence of vancomycin resistance during therapy against methicillin-resistant Staphylococcus aureus in a burn patient--importance of low-level resistance to vancomycin.Haraga I, Nomura S, Fukamachi S, Ohjimi H, Hanaki H, Hiramatsu K, Nagayama AInt J Infect Dis10.1016/s1201-9712(02)90165-72002Anti-Bacterial Agents/pharmacology/*therapeutic use, Child, Preschool, Culture Media, Genotype, Humans, Male, *Methicillin Resistance, Microbial Sensitivity Tests, Phenotype, Staphylococcal Infections/*drug therapy/microbiology, Staphylococcus aureus/classification/*drug effects/genetics/isolation & purification, Treatment Outcome, Vancomycin/pharmacology/*therapeutic use, *Vancomycin Resistance, Wound Infection/*drug therapy/microbiologyCultivation
Pathogenicity12808315Efficacy of vancomycin-beta-lactam combinations against heterogeneously vancomycin-resistant Staphylococcus aureus (hetero-VRSA).Kim YS, Kiem S, Yun HJ, Jung SI, Oh WS, Kim SW, Peck KR, Lee NY, Song JHJ Korean Med Sci10.3346/jkms.2003.18.3.3192003Anti-Bacterial Agents/*pharmacology, Cefotaxime/pharmacology, Drug Synergism, Humans, In Vitro Techniques, Microbial Sensitivity Tests, Oxacillin/*pharmacology, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, Vancomycin Resistance, beta-Lactam Resistance
Pathogenicity14574841[Epidemiological investigation of MRSA with antagonistic effects of beta-lactam antibiotic and vancomycin].Yamaguchi Y, Hanaki H, Barada K, Inamatu T, Sunakawa KKansenshogaku Zasshi10.11150/kansenshogakuzasshi1970.77.6612003Anti-Bacterial Agents/*pharmacology, Drug Antagonism, Humans, Japan, *Methicillin Resistance, Retrospective Studies, Staphylococcus aureus/*drug effects/isolation & purification, Vancomycin/*pharmacology, beta-Lactams/pharmacologyEnzymology
Metabolism15141945Nucleotide substitutions in Staphylococcus aureus strains, Mu50, Mu3, and N315.Ohta T, Hirakawa H, Morikawa K, Maruyama A, Inose Y, Yamashita A, Oshima K, Kuroda M, Hattori M, Hiramatsu K, Kuhara S, Hayashi HDNA Res10.1093/dnares/11.1.512004Bacterial Proteins/*genetics/metabolism, Cell Wall/genetics/metabolism, Drug Resistance, Microbial/genetics, Methicillin Resistance/*genetics, *Mutation, Open Reading Frames/genetics, Staphylococcus aureus/enzymology/*genetics, Vancomycin Resistance/*geneticsEnzymology
Pathogenicity15164965In vitro combined bactericidal activity of cefpirome and glycopeptides against glycopeptides and oxacillin-resistant staphylococci.Bergeret M, Boutros N, Raymond JInt J Antimicrob Agents10.1016/j.ijantimicag.2003.08.0092004Anti-Bacterial Agents/*administration & dosage, Cephalosporins/*administration & dosage, Cross Infection/drug therapy/microbiology, Drug Resistance, Multiple, Bacterial, Drug Therapy, Combination/*administration & dosage, *Glycopeptides, Humans, In Vitro Techniques, Oxacillin/pharmacology, Staphylococcal Infections/drug therapy/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, Staphylococcus epidermidis/*drug effects/isolation & purification, Staphylococcus haemolyticus/*drug effects/isolation & purificationEnzymology
Pathogenicity15715719Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.Nonhoff C, Denis O, Struelens MJClin Microbiol Infect10.1111/j.1469-0691.2004.01060.x2005Belgium/epidemiology, Culture Media/chemistry, *Drug Resistance, Multiple, Bacterial, Hospitals, Humans, *Methicillin Resistance, Microbial Sensitivity Tests/methods, Prevalence, Sensitivity and Specificity, Staphylococcal Infections/epidemiology/*microbiology, Staphylococcus aureus/*drug effects/genetics, Teicoplanin/*pharmacology, Vancomycin/*pharmacologyCultivation
Transcriptome15855508A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.McAleese F, Petersen P, Ruzin A, Dunman PM, Murphy E, Projan SJ, Bradford PAAntimicrob Agents Chemother10.1128/AAC.49.5.1865-1871.20052005Anti-Bacterial Agents/*pharmacology, DNA Probes, DNA, Bacterial/genetics, Drug Resistance, Bacterial, Gene Expression Regulation, Bacterial/genetics, Genes, Bacterial/genetics, Microbial Sensitivity Tests, Minocycline/*analogs & derivatives/*pharmacology, Mutation/genetics, Oligonucleotide Array Sequence Analysis, Plasmids/genetics, RNA, Bacterial/genetics, Reverse Transcriptase Polymerase Chain Reaction, Staphylococcus aureus/*drug effects, TigecyclinePathogenicity
Pathogenicity16130290[The combined effect of methicillin and teicoplanin against Staphylococcus aureus strains investigated in vitro].Mlynarczyk A, Mlynarczyk G, Luczak MMed Dosw Mikrobiol2005Anti-Bacterial Agents/pharmacology, Drug Synergism, Drug Therapy, Combination, In Vitro Techniques, Methicillin/*pharmacology, Methicillin Resistance, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects, Teicoplanin/*pharmacology
Pathogenicity16569879Autolytic properties of glycopeptide-intermediate Staphylococcus aureus Mu50.Utaida S, Pfeltz RF, Jayaswal RK, Wilkinson BJAntimicrob Agents Chemother10.1128/AAC.50.4.1541-1545.20062006Anti-Bacterial Agents/*pharmacology, Bacteriolysis/*drug effects, Glycopeptides/metabolism/*pharmacology, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects/metabolism, Vancomycin/pharmacologyMetabolism
Pathogenicity17954695Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.Neoh HM, Cui L, Yuzawa H, Takeuchi F, Matsuo M, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00534-072007Anti-Bacterial Agents/pharmacology, Bacterial Proteins/*genetics/metabolism, *Gene Expression Regulation, Bacterial, Genome, Bacterial/genetics, Humans, Microbial Sensitivity Tests, *Mutation, Oligonucleotide Array Sequence Analysis, Phenotype, Sequence Analysis, DNA, *Signal Transduction, Staphylococcus aureus/*drug effects/genetics/growth & development/metabolism, Vancomycin/pharmacology, Vancomycin Resistance/*geneticsTranscriptome
Pathogenicity17962217Evaluation of Fourier transform infrared spectroscopy for the rapid identification of glycopeptide-intermediate Staphylococcus aureus.Amiali NM, Mulvey MR, Berger-Bachi B, Sedman J, Simor AE, Ismail AAJ Antimicrob Chemother10.1093/jac/dkm4002007Algorithms, Anti-Bacterial Agents/pharmacology, Drug Resistance, Bacterial/*drug effects, Glycopeptides/*pharmacology, Humans, Methicillin Resistance/drug effects, Microbial Sensitivity Tests, Principal Component Analysis, Reproducibility of Results, Spectroscopy, Fourier Transform Infrared/methods, Staphylococcal Infections/microbiology, Staphylococcus aureus/classification/drug effects/*isolation & purificationPhylogeny
Pathogenicity18297444The antagonistic effects of a combination of vancomycin and minocycline in Staphylococcus aureus with heterogeneous resistance to vancomycin.Oshiro T, Nagasawa Z, Hanaki H, Ikeda-Dantsuji Y, Nagayama AJ Infect Chemother10.1007/s10156-007-0569-92008Anti-Bacterial Agents/*pharmacology, Bacteriolysis, *Drug Resistance, Multiple, Bacterial, Humans, Methicillin Resistance, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Minocycline/*pharmacology, Staphylococcal Infections/microbiology, Staphylococcus aureus/classification/cytology/*drug effects, Vancomycin/*pharmacology, Vancomycin ResistancePhylogeny
Pathogenicity18445959Modified PAP method to detect heteroresistance to vancomycin among methicillin resistant Staphylococcus aureus isolates at a tertiary care hospital.Iyer RN, Hittinahalli VIndian J Med Microbiol10.4103/0255-0857.405372008Anti-Bacterial Agents/*pharmacology, Hospitals, Humans, *Methicillin Resistance, Microbial Sensitivity Tests/*methods, Predictive Value of Tests, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, *Vancomycin ResistanceEnzymology
Enzymology18984644Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations.Leonard SN, Rybak MJJ Antimicrob Chemother10.1093/jac/dkn4392008Anti-Bacterial Agents/*pharmacokinetics/*pharmacology, Colony Count, Microbial, Daptomycin/*pharmacokinetics/*pharmacology, Humans, Methicillin-Resistant Staphylococcus aureus/*drug effects, Microbial Viability, Models, Theoretical, Vancomycin/*pharmacokinetics/*pharmacology, *Vancomycin ResistancePathogenicity
Pathogenicity19155225Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.Hegde SS, Difuntorum S, Skinner R, Trumbull J, Krause KMJ Antimicrob Chemother10.1093/jac/dkp0012009Aminoglycosides/administration & dosage/*therapeutic use, Animals, Anti-Bacterial Agents/pharmacology/*therapeutic use, Bacteremia/*drug therapy/microbiology, Blood/microbiology, Colony Count, Microbial, *Drug Resistance, Bacterial, Female, Glycopeptides/pharmacology, Lipoglycopeptides, Mice, Spleen/microbiology, Staphylococcal Infections/*drug therapy/microbiology, Staphylococcus aureus/*drug effects, Treatment Outcome, Vancomycin/administration & dosage/therapeutic use
Genetics19451283Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00834-082009Anti-Bacterial Agents/*pharmacology, Blotting, Northern, Drug Resistance, Multiple, Bacterial, Genome, Bacterial/genetics, Imipenem/*pharmacology, Microbial Sensitivity Tests, Mutation, Sequence Analysis, DNA, Staphylococcus aureus/*drug effects/genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics, beta-Lactams/pharmacologyTranscriptome
Pathogenicity19506056Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA.Horne KC, Howden BP, Grabsch EA, Graham M, Ward PB, Xie S, Mayall BC, Johnson PD, Grayson MLAntimicrob Agents Chemother10.1128/AAC.01365-082009Adolescent, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus/drug effects/*physiology, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/*drug therapy/*microbiology/physiopathology, Staphylococcus aureus/drug effects/*physiology, Treatment Outcome, Vancomycin/*therapeutic use, Young Adult
Pathogenicity20139142Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.Hegde SS, Skinner R, Lewis SR, Krause KM, Blais J, Benton BMJ Antimicrob Chemother10.1093/jac/dkq0282010Aminoglycosides/administration & dosage/*pharmacology/*therapeutic use, Animals, Anti-Bacterial Agents/administration & dosage/*pharmacology/*therapeutic use, Bacteremia/drug therapy, Blood/microbiology, Disease Models, Animal, Female, Lipoglycopeptides, Mice, Microbial Sensitivity Tests, Spleen/microbiology, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Treatment Outcome, *Vancomycin Resistance
Pathogenicity20392906First detection of an invasive Staphylococcus aureus strain (D958) with reduced susceptibility to glycopeptides in Saudi Arabia.Al-Obeid S, Haddad Q, Cherkaoui A, Schrenzel J, Francois PJ Clin Microbiol10.1128/JCM.00954-092010Aged, Anti-Bacterial Agents/analysis/*pharmacology/therapeutic use, Bacterial Typing Techniques, Blood/microbiology, Chromosomes, Bacterial, Cluster Analysis, DNA Fingerprinting, DNA, Bacterial/genetics, Genes, Bacterial, Genotype, Humans, Lysostaphin/pharmacology, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/*isolation & purification, Microarray Analysis, Microbial Sensitivity Tests, Microbial Viability/drug effects, Plasmids, Saudi Arabia, Sepsis/*microbiology, Serum/chemistry, Staphylococcal Infections/*microbiology, Teicoplanin/pharmacology, Vancomycin/analysis/*pharmacology/therapeutic use, *Vancomycin ResistanceGenetics
Pathogenicity21048008Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method.Satola SW, Farley MM, Anderson KF, Patel JBJ Clin Microbiol10.1128/JCM.01128-102010Anti-Bacterial Agents/*pharmacology, Culture Media/chemistry, Humans, Microbial Sensitivity Tests/methods, Sensitivity and Specificity, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, *Vancomycin ResistanceCultivation
21374408Detection Methods of Glycopeptide-Resistant Staphylococcus aureus I : Susceptibility Testing.Hanaki H, Hiramatsu KMethods Mol Med10.1385/1-59259-077-2:852001
21374409Detection Methods for Glycopeptide-Resistant Staphylococcus aureus II : Cell Wall Analysis.Hanaki H, Hiramatsu KMethods Mol Med10.1385/1-59259-077-2:932001
Pathogenicity21490190Detection of intermediately vancomycin-susceptible and heterogeneous Staphylococcus aureus isolates: comparison of Etest and Agar screening methods.Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib RJ Clin Microbiol10.1128/JCM.01435-102011Agar, Culture Media/chemistry, Humans, Mass Screening/methods, Microbial Sensitivity Tests/methods, Sensitivity and Specificity, Staphylococcal Infections/microbiology, Staphylococcus aureus/*drug effects/isolation & purification, *Vancomycin ResistanceCultivation
Pathogenicity21525024Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.Khatib R, Jose J, Musta A, Sharma M, Fakih MG, Johnson LB, Riederer K, Shemes SJ Antimicrob Chemother10.1093/jac/dkr1692011Adult, Aged, Anti-Bacterial Agents/*pharmacology/therapeutic use, Bacteremia/*drug therapy/*microbiology, Female, Humans, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/isolation & purification, Microbial Sensitivity Tests, Middle Aged, Staphylococcal Infections/*drug therapy/microbiology, Treatment Outcome, Vancomycin/*pharmacology/therapeutic use, *Vancomycin ResistanceEnzymology
Phylogeny21625460Sequence diversities of serine-aspartate repeat genes among Staphylococcus aureus isolates from different hosts presumably by horizontal gene transfer.Xue H, Lu H, Zhao XPLoS One10.1371/journal.pone.00203322011Animals, Aspartic Acid/*genetics, Base Sequence, Cattle, DNA, Bacterial, Female, *Gene Transfer, Horizontal, *Genes, Bacterial, Humans, Mastitis, Bovine/microbiology, Molecular Sequence Data, Phylogeny, Sequence Homology, Nucleic Acid, Serine/*genetics, Staphylococcus aureus/classification/*genetics/isolation & purificationPathogenicity
Pathogenicity21746940Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3.Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00398-112011Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/*genetics, DNA-Directed RNA Polymerases/*genetics, Microbial Sensitivity Tests, Mutation, Rifampin/pharmacology, Staphylococcus aureus/*drug effects/*genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics
Phenotype23113753Presence of both heterogeneous vancomycin-intermediate resistance and beta-lactam antibiotic-induced vancomycin resistance phenotypes is associated with the outcome in methicillin-resistant Staphylococcus aureus bloodstream infection.Takata T, Miyazaki M, Futo M, Hara S, Shiotsuka S, Kamimura H, Yoshimura H, Matsunaga A, Nishida T, Ishikura H, Ishikawa T, Tamura K, Tsuji BTScand J Infect Dis10.3109/00365548.2012.7232212012Adolescent, Adult, Aged, Aged, 80 and over, Analysis of Variance, Anti-Bacterial Agents/*pharmacology, Bacteremia/drug therapy/*microbiology, Comorbidity, Female, Humans, Logistic Models, Male, Methicillin-Resistant Staphylococcus aureus/*drug effects/isolation & purification, Microbial Sensitivity Tests, Middle Aged, Phenotype, Retrospective Studies, Staphylococcal Infections/drug therapy/*microbiology, Treatment Outcome, Vancomycin Resistance, beta-Lactams/*pharmacologyPathogenicity
Phylogeny23442205Global analysis of transcriptional regulators in Staphylococcus aureus.Ibarra JA, Perez-Rueda E, Carroll RK, Shaw LNBMC Genomics10.1186/1471-2164-14-1262013Bacterial Proteins/classification/*genetics, Gene Regulatory Networks, *Genes, Bacterial, Methicillin-Resistant Staphylococcus aureus/genetics, Phylogeny, Sigma Factor/genetics, Staphylococcus aureus/*genetics, Transcription Factors/classification/*genetics
Pathogenicity24018261Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3.Matsuo M, Cui L, Kim J, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00425-132013Anti-Bacterial Agents/*pharmacology, Cell Wall/ultrastructure, DNA-Directed RNA Polymerases/genetics, *Gene Expression Regulation, Bacterial, Genes, Bacterial, *Genome, Bacterial, High-Throughput Nucleotide Sequencing, Humans, Microbial Sensitivity Tests, *Mutation, Nucleoside-Phosphate Kinase/genetics, Staphylococcal Infections/microbiology, Staphylococcus aureus/drug effects/*genetics/growth & development/isolation & purification, Vancomycin/*pharmacology, Vancomycin Resistance/*geneticsGenetics
Phenotype24841271"Slow VISA," a novel phenotype of vancomycin resistance, found in vitro in heterogeneous vancomycin-intermediate Staphylococcus aureus strain Mu3.Saito M, Katayama Y, Hishinuma T, Iwamoto A, Aiba Y, Kuwahara-Arai K, Cui L, Matsuo M, Aritaka N, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.02470-132014Anti-Bacterial Agents/pharmacology, Bacterial Proteins/genetics, Cell Wall/drug effects/genetics/microbiology, DNA-Directed RNA Polymerases/genetics, Genome, Bacterial/genetics, Microbial Sensitivity Tests/methods, Mutation/genetics, Phenotype, Staphylococcus aureus/*drug effects/*genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*geneticsPathogenicity
Pathogenicity24957836Exposure of Staphylococcus aureus to subinhibitory concentrations of beta-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus.Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydiere AM, Laurent F, Reix P, Dumitrescu O, Vandenesch FAntimicrob Agents Chemother10.1128/AAC.02574-142014Anti-Bacterial Agents/administration & dosage/*pharmacology, Ceftazidime/administration & dosage/pharmacology, Ceftriaxone/administration & dosage/pharmacology, Drug Resistance, Bacterial, Imipenem/administration & dosage/pharmacology, Methicillin Resistance/drug effects, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Staphylococcus aureus/*drug effects/ultrastructure, Vancomycin/administration & dosage/pharmacology, Vancomycin Resistance/*drug effects, beta-Lactams/administration & dosage/*pharmacology
Pathogenicity26203181Adaptation to vancomycin pressure of multiresistant Staphylococcus capitis NRCS-A involved in neonatal sepsis.Butin M, Martins-Simoes P, Picaud JC, Kearns A, Claris O, Vandenesch F, Laurent F, Rasigade JPJ Antimicrob Chemother10.1093/jac/dkv2172015*Adaptation, Biological, Anti-Bacterial Agents/*pharmacology/therapeutic use, Cell Wall/ultrastructure, Humans, Infant, Newborn, Microbial Sensitivity Tests, Microscopy, Electron, Transmission, Sepsis/drug therapy/*microbiology, Serial Passage, Staphylococcal Infections/drug therapy/*microbiology, Staphylococcus/*drug effects/growth & development/ultrastructure, Vancomycin/*pharmacology/therapeutic use
Pathogenicity26311860Screening for Intermediately Vancomycin-Susceptible and Vancomycin-Heteroresistant Staphylococcus aureus by Use of Vancomycin-Supplemented Brain Heart Infusion Agar Biplates: Defining Growth Interpretation Criteria Based on Gold Standard Confirmation.Khatib R, Riederer K, Sharma M, Shemes S, Iyer SP, Szpunar SJ Clin Microbiol10.1128/JCM.01620-152015Agar/pharmacology, Anti-Bacterial Agents/*pharmacology, Culture Media/*pharmacology, Humans, Methicillin-Resistant Staphylococcus aureus/drug effects/*growth & development/isolation & purification, Microbial Sensitivity Tests, Staphylococcal Infections/microbiology, Vancomycin/*pharmacology, Vancomycin Resistance/*geneticsCultivation
Metabolism27067329Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus.Katayama Y, Sekine M, Hishinuma T, Aiba Y, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00420-162016Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/genetics/metabolism, Bacteriolysis/genetics, Cell Wall/*drug effects/genetics/metabolism/ultrastructure, DNA-Directed RNA Polymerases/genetics/metabolism, Formate Dehydrogenases/genetics/metabolism, *Gene Expression Regulation, Bacterial, Genotype, Membrane Proteins/genetics/metabolism, Microbial Sensitivity Tests, *Mutation, Phenotype, Reverse Genetics/methods, Staphylococcus aureus/*drug effects/genetics/metabolism/ultrastructure, Vancomycin/*pharmacology, Vancomycin Resistance/*geneticsPhenotype
Transcriptome27476981Complete sequence of a plasmid from a bovine methicillin-resistant Staphylococcus aureus harbouring a novel ica-like gene cluster in addition to antimicrobial and heavy metal resistance genes.Fessler AT, Zhao Q, Schoenfelder S, Kadlec K, Brenner Michael G, Wang Y, Ziebuhr W, Shen J, Schwarz SVet Microbiol10.1016/j.vetmic.2016.07.0102016Animals, Anti-Infective Agents/pharmacology, Bacterial Proteins/genetics, Biofilms/*growth & development, Cattle, Cattle Diseases/epidemiology/*microbiology, Drug Resistance, Multiple, Bacterial/*genetics, Metals, Heavy/toxicity, Methicillin-Resistant Staphylococcus aureus/drug effects/*genetics/isolation & purification/pathogenicity, Microbial Sensitivity Tests/veterinary, Multigene Family, Plasmids/*genetics, Sequence Analysis, DNA/veterinary, Staphylococcal Infections/epidemiology/microbiology/*veterinary, Virulence/geneticsEnzymology
Pathogenicity28139739Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA.Lai CC, Chen CC, Chuang YC, Tang HJSci Rep10.1038/srep417582017Anti-Bacterial Agents/*pharmacology, Cephalosporins/*pharmacology, Drug Synergism, Glycopeptides/*pharmacology, Humans, Microbial Sensitivity Tests, Staphylococcus aureus/*drug effects, Teicoplanin/*pharmacology, Vancomycin/*pharmacology
Pathogenicity28289032VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.Dai Y, Chang W, Zhao C, Peng J, Xu L, Lu H, Zhou S, Ma XAntimicrob Agents Chemother10.1128/AAC.02740-162017Anti-Bacterial Agents/*pharmacology, Bacterial Proteins/biosynthesis/*genetics/*metabolism, Bacterial Toxins/biosynthesis, DNA-Binding Proteins/*metabolism, Hemolysin Proteins/biosynthesis, Microbial Sensitivity Tests, Porins/biosynthesis, Promoter Regions, Genetic/*genetics, Quorum Sensing/drug effects, RNA, Bacterial/biosynthesis, Sphingomyelin Phosphodiesterase/biosynthesis, Staphylococcal Infections/drug therapy/microbiology/pathology, Staphylococcus aureus/drug effects/*genetics/pathogenicity, Trans-Activators/*genetics, Transcription Factors/biosynthesis, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics, Virulence/drug effects, Virulence Factors/biosynthesisMetabolism
Pathogenicity28827421Prevalence of Slow-Growth Vancomycin Nonsusceptibility in Methicillin-Resistant Staphylococcus aureus.Katayama Y, Azechi T, Miyazaki M, Takata T, Sekine M, Matsui H, Hanaki H, Yahara K, Sasano H, Asakura K, Takaku T, Ochiai T, Komatsu N, Chambers HFAntimicrob Agents Chemother10.1128/AAC.00452-172017Anti-Bacterial Agents/*pharmacology, DNA-Directed RNA Polymerases/genetics, High-Throughput Nucleotide Sequencing, Humans, Methicillin-Resistant Staphylococcus aureus/*drug effects/*genetics/growth & development, Microbial Sensitivity Tests, Mupirocin/*pharmacology, Mutation/genetics, Polymorphism, Single Nucleotide/genetics, Vancomycin/*pharmacology, Vancomycin Resistance/*genetics
Pathogenicity29158272Combination Antibiotic Exposure Selectively Alters the Development of Vancomycin Intermediate Resistance in Staphylococcus aureus.Zheng X, Berti AD, McCrone S, Roch M, Rosato AE, Rose WE, Chen BAntimicrob Agents Chemother10.1128/AAC.02100-172018Anti-Bacterial Agents/*pharmacology, Drug Therapy, Combination, Humans, Microbial Sensitivity Tests/methods, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/*drug effects, Vancomycin/*pharmacology, Vancomycin Resistance/*drug effects, beta-Lactams/pharmacology
Pathogenicity30455230Identification of a Novel Gene Associated with High-Level beta-Lactam Resistance in Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain Mu3 and Methicillin-Resistant S. aureus Strain N315.Matsuo M, Yamamoto N, Hishinuma T, Hiramatsu KAntimicrob Agents Chemother10.1128/AAC.00712-182019Anti-Bacterial Agents/*pharmacology, Codon, Nonsense/genetics, Methicillin/pharmacology, Methicillin-Resistant Staphylococcus aureus/*drug effects/*genetics, Microbial Sensitivity Tests, Staphylococcus aureus/drug effects/genetics, Vancomycin/*pharmacology, beta-Lactam Resistance/genetics/*physiology
Pathogenicity31009806VraSR has an important role in immune evasion of Staphylococcus aureus with low level vancomycin resistance.Gao C, Dai Y, Chang W, Fang C, Wang Z, Ma XMicrobes Infect10.1016/j.micinf.2019.04.0032019Bacterial Adhesion/genetics, Bacterial Proteins/genetics/*immunology, Biofilms/growth & development, Cell Wall/genetics/metabolism, DNA-Binding Proteins/genetics/*immunology, HeLa Cells, Humans, Immune Evasion, Microbial Viability/genetics, Mutation, Neutrophils/microbiology, Staphylococcal Infections/*microbiology, Staphylococcus aureus/*genetics/*immunology, *Vancomycin Resistance/genetics/immunologyMetabolism
31214151Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Uses the VraSR Regulatory System to Modulate Autophagy for Increased Intracellular Survival in Macrophage-Like Cell Line RAW264.7.Dai Y, Gao C, Chen L, Chang W, Yu W, Ma X, Li JFront Microbiol10.3389/fmicb.2019.012222019
Pathogenicity32001173Protective activity of anti-lipoteichoic acid monoclonal antibody in single or combination therapies in methicillin-resistant Staphylococcus aureus-induced murine sepsis models.Ohsawa H, Baba T, Enami J, Hiramatsu KJ Infect Chemother10.1016/j.jiac.2019.12.0182020Animals, Anti-Bacterial Agents/pharmacology/therapeutic use, Antibodies, Bacterial, Antibodies, Monoclonal/*pharmacology/therapeutic use, Daptomycin/pharmacology/therapeutic use, Disease Models, Animal, Drug Therapy, Combination, Humans, Linezolid/pharmacology/therapeutic use, Lipopolysaccharides/*antagonists & inhibitors/metabolism, Methicillin-Resistant Staphylococcus aureus/*drug effects, Mice, Sepsis/*drug therapy, Staphylococcal Infections/*drug therapy, Staphylococcus aureus/drug effects, Teichoic Acids/*antagonists & inhibitors/metabolism, Vancomycin/pharmacology/therapeutic useMetabolism
Enzymology32233172Comparison of In Vivo Pharmacokinetics and Pharmacodynamics of Vancomycin Products Available in Korea.Kim HK, Choi SM, Kang G, Park KH, Lee DG, Park WB, Rhee SJ, Lee S, Jung SI, Jang HCYonsei Med J10.3349/ymj.2020.61.4.3012020Animals, Anti-Bacterial Agents/pharmacokinetics/pharmacology/therapeutic use, Disease Models, Animal, Drugs, Generic/*pharmacokinetics/pharmacology/*therapeutic use, Methicillin-Resistant Staphylococcus aureus/*drug effects, Mice, Microbial Sensitivity Tests, Republic of Korea, Staphylococcal Infections/complications/*drug therapy/microbiology, Staphylococcus aureus/drug effects, Thigh/microbiology, Treatment Failure, Vancomycin/*pharmacokinetics/pharmacology/*therapeutic usePathogenicity
Pathogenicity33097426Differentiation of qacA and qacB using high-resolution melt curve analysis, and both qacA and qacB but not qacC or norA types increase chlorhexidine minimal inhibitory concentrations in Staphylococcus aureus isolates.Lin KH, Lin CY, Huang CC, Ho YL, Yang SF, Ho CMJ Microbiol Immunol Infect10.1016/j.jmii.2020.09.0062020Anti-Infective Agents, Local/*pharmacology, Bacterial Proteins/*genetics, Chlorhexidine/*pharmacology, Disinfectants/*pharmacology, Drug Resistance, Bacterial/genetics, Humans, Membrane Transport Proteins/*genetics, Methicillin-Resistant Staphylococcus aureus/*drug effects/genetics/isolation & purification, Microbial Sensitivity Tests, Multidrug Resistance-Associated Proteins/genetics, Staphylococcal Infections/drug therapy/microbiology/prevention & controlEnzymology
Phenotype33519759Variable Release of Lipoteichoic Acid From Staphylococcus aureus Bloodstream Isolates Relates to Distinct Clinical Phenotypes, Strain Background, and Antibiotic Exposure.Algorri M, Jorth P, Wong-Beringer AFront Microbiol10.3389/fmicb.2020.6092802021
Pathogenicity34784023Efficacy and mechanism of carvacrol with octanoic acid against mastitis causing multi-drug-resistant pathogens.Rani S, Singh H, Ram CBraz J Microbiol10.1007/s42770-021-00639-42021Animals, Anti-Bacterial Agents/pharmacology, Caprylates/pharmacology, Cattle, Cymenes, Escherichia coli, Female, Humans, *Mastitis, Microbial Sensitivity Tests, *Oils, Volatile/pharmacology, *Pharmaceutical Preparations
Pathogenicity35022718Heterogeneous vancomycin resistance in Staphylococcus aureus does not predict development of vancomycin resistance upon vancomycin pressure.Gaillard T, Dupieux-Chabert C, Butin M, Dumitrescu O, Naceur O, Bouveyron C, Martra A, Bes M, Tristan A, Vandenesch F, Lina G, Laurent F, Rasigade JPJ Antimicrob Chemother10.1093/jac/dkab4882022Anti-Bacterial Agents/pharmacology/therapeutic use, Humans, *Methicillin-Resistant Staphylococcus aureus, Microbial Sensitivity Tests, *Staphylococcal Infections/drug therapy, Staphylococcus aureus, Vancomycin/pharmacology, Vancomycin Resistance
35758685Subinhibitory Concentrations of Antibiotics Exacerbate Staphylococcal Infection by Inducing Bacterial Virulence.Gao P, Wei Y, Wan RE, Wong KW, Iu HTV, Tai SSC, Li Y, Yam HCB, Halebeedu Prakash P, Chen JHK, Ho PL, Yuen KY, Davies J, Kao RYTMicrobiol Spectr10.1128/spectrum.00640-222022Animals, Anti-Bacterial Agents/pharmacology, *Bacteremia/drug therapy, *Methicillin-Resistant Staphylococcus aureus, Mice, Microbial Sensitivity Tests, *Peritonitis/drug therapy, Reproducibility of Results, *Staphylococcal Infections/drug therapy/microbiology, Tetracycline/pharmacology, Virulence Factors, beta-Lactams/pharmacology

Reference

@idauthorstitledoi/urlcatalogue
20215Parte, A.C., Sardà Carbasse, J., Meier-Kolthoff, J.P., Reimer, L.C. and Göker, M.List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ10.1099/ijsem.0.004332
39515Curators of the CIPhttps://catalogue-crbip.pasteur.fr/fiche_catalogue.xhtml?crbip=CIP%20106415Collection of Institut Pasteur (CIP 106415)
56732Curators of the CCUGhttps://www.ccug.se/strain?id=45316Culture Collection University of Gothenburg (CCUG) (CCUG 45316)
66792Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg OvermannAutomatically annotated for the DiASPora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information)https://diaspora-project.de/progress.html#genomes
68375Automatically annotated from API ID32STA
68382Automatically annotated from API zym
69480Julia Koblitz, Joaquim Sardà, Lorenz Christian Reimer, Boyke Bunk, Jörg OvermannPredictions based on genome sequence made in the Diaspora project (Digital Approaches for the Synthesis of Poorly Accessible Biodiversity Information)https://diaspora-project.de/progress.html#genomes